

Marina F Caskey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8008077/publications.pdf>

Version: 2024-02-01

71
papers

17,394
citations

41258

49
h-index

85405

71
g-index

103
all docs

103
docs citations

103
times ranked

22172
citing authors

#	ARTICLE	IF	CITATIONS
1	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020, 584, 437-442.	13.7	1,742
2	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	13.7	1,355
3	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020, 9, .	2.8	1,239
4	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
5	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020, 182, 828-842.e16.	13.5	724
6	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. <i>Nature</i> , 2015, 522, 487-491.	13.7	665
7	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431.	13.7	610
8	Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. <i>Journal of Experimental Medicine</i> , 2009, 206, 1589-1602.	4.2	555
9	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	503
10	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. <i>Nature</i> , 2016, 535, 556-560.	13.7	400
11	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. <i>Nature Medicine</i> , 2017, 23, 185-191.	15.2	399
12	HIV-1 Integration Landscape during Latent and Active Infection. <i>Cell</i> , 2015, 160, 420-432.	13.5	393
13	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018, 561, 479-484.	13.7	392
14	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	379
15	Plasma Neutralization of the SARS-CoV-2 Omicron Variant. <i>New England Journal of Medicine</i> , 2022, 386, 599-601.	13.9	371
16	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	5.8	332
17	Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. <i>Science</i> , 2016, 352, 1001-1004.	6.0	302
18	Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. <i>Cell</i> , 2017, 169, 597-609.e11.	13.5	279

#	ARTICLE	IF	CITATIONS
19	The microbial mimic poly IC induces durable and protective CD4 ⁺ T cell immunity together with a dendritic cell targeted vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2574-2579.	3.3	276
20	Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. Journal of Experimental Medicine, 2011, 208, 2357-2366.	4.2	263
21	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science, 2016, 352, 997-1001.	6.0	263
22	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	13.7	239
23	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	6.6	230
24	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature, 2022, 607, 128-134.	13.7	197
25	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature Medicine, 2018, 24, 1701-1707.	15.2	195
26	Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nature Medicine, 2019, 25, 547-553.	15.2	191
27	Circulating precursors of human CD1c+ and CD141+ dendritic cells. Journal of Experimental Medicine, 2015, 212, 401-413.	4.2	187
28	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature, 2021, 600, 512-516.	13.7	174
29	Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7908-E7916.	3.3	164
30	In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. PLoS ONE, 2011, 6, e19252.	1.1	160
31	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nature Medicine, 2021, 27, 2085-2098.	15.2	146
32	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. Lancet HIV, 2019, 6, e259-e268.	2.1	139
33	Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. Nature Medicine, 2018, 24, 604-609.	15.2	124
34	Persistent cellular immunity to SARS-CoV-2 infection. Journal of Experimental Medicine, 2021, 218, .	4.2	115
35	Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nature Medicine, 2020, 26, 222-227.	15.2	108
36	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	15.2	96

#	ARTICLE	IF	CITATIONS
37	Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. <i>Journal of Experimental Medicine</i> , 2019, 216, 2253-2264.	4.2	92
38	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. <i>Immunity</i> , 2022, 55, 998-1012.e8.	6.6	86
39	Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. <i>Journal of Experimental Medicine</i> , 2018, 215, 2311-2324.	4.2	84
40	Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	75
41	Prolonged viral suppression with anti-HIV-1 antibody therapy. <i>Nature</i> , 2022, 606, 368-374.	13.7	75
42	Clinical Manifestations Associated with HTLV Type I Infection: A Cross-Sectional Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 365-371.	0.5	71
43	ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. <i>Cell Reports Medicine</i> , 2020, 1, 100123.	3.3	70
44	A Randomized Open-Label Study of 3- Versus 5-Drug Combination Antiretroviral Therapy in Newly HIV-1-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 140-147.	0.9	69
45	Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. <i>New England Journal of Medicine</i> , 2016, 375, 2019-2021.	13.9	66
46	Relationship between intact HIV-1 proviruses in circulating CD4 ⁺ T cells and rebound viruses emerging during treatment interruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11341-E11348.	3.3	65
47	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. <i>Nature Communications</i> , 2021, 12, 4886.	5.8	65
48	Combination anti-HIV antibodies provide sustained virological suppression. <i>Nature</i> , 2022, 606, 375-381.	13.7	65
49	Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 366-373.	1.5	64
50	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019, 14, e0219142.	1.1	58
51	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
52	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	52
53	Broadly neutralizing antibodies for the treatment and prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 49-55.	1.5	49
54	Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. <i>Journal of Clinical Virology</i> , 2011, 51, 54-58.	1.6	48

#	ARTICLE	IF	CITATIONS
55	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. <i>Cell Host and Microbe</i> , 2020, 28, 335-349.e6.	5.1	48
56	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. <i>Journal of Virology</i> , 2021, 95, .	1.5	47
57	Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine. <i>PLoS ONE</i> , 2010, 5, e8816.	1.1	47
58	Brain Magnetic Resonance Imaging White Matter Lesions Are Frequent in HTLV-I Carriers and Do Not Discriminate from HAM/TSP. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1499-1504.	0.5	46
59	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 2018, 92, .	1.5	39
60	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. <i>Lancet Microbe</i> , The, 2022, 3, e203-e214.	3.4	33
61	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates. <i>Journal of Virology</i> , 2021, 95, .	1.5	18
62	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , 2021, 65, 103252.	2.7	12
63	TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. <i>Clinical Chemistry</i> , 2021, 67, 1249-1258.	1.5	12
64	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
65	Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration. <i>Antibodies</i> , 2020, 9, 36.	1.2	7
66	Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention. <i>Clinical Trials</i> , 2021, 18, 17-27.	0.7	6
67	The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infectionâ€”study protocol for a two-stage randomised phase II trial. <i>Trials</i> , 2022, 23, 263.	0.7	6
68	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
69	Delivery of anti-HIV bNAbs by viral vectors. <i>Lancet HIV</i> ,the, 2019, 6, e207-e208.	2.1	4
70	Broadly Neutralizing Antihuman Immunodeficiency Virus Antibodies in Infants: Promising New Tools for Prevention of Mother-to-Child Transmission?. <i>Journal of Infectious Diseases</i> , 2020, 222, 525-527.	1.9	1
71	A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers. <i>Blood</i> , 2012, 120, 4124-4124.	0.6	0